United Therapeutics (UTHR) Net Margin (2009 - 2026)

United Therapeutics has disclosed Net Margin across 18 years of filings, most recently posting 42.51% for Q2 2026.

• In Q2 2026, Net Margin rose 376.0% year-over-year to 42.51%; the TTM figure through Jun 2026 stood at 41.56% (up 120.0% YoY), while the FY2025 annual figure was 41.94%, up 40.0% from the prior year.
• Net Margin came in at 42.51% for Q2 2026 at United Therapeutics, up from 35.18% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 51.94% in Q1 2022 to a low of 24.84% in Q2 2022.
• Average Net Margin over 5 years is 40.67%, with a median of 41.82% recorded in 2025.
• The largest YoY upside for Net Margin was 4447 bps in 2022 against a maximum downside of 1381 bps in 2022.
• Over 5 years, Net Margin stood at 26.88% in 2022, then surged by 31 bps to 35.32% in 2023, then advanced by 16 bps to 40.94% in 2024, then gained by 13 bps to 46.1% in 2025, then declined by 8 bps to 42.51% in 2026.
• Per Business Quant data, the three most recent Net Margin figures were 42.51% in Q2 2026, 35.18% in Q1 2026, and 46.1% in Q4 2025.